In this study, we used serum samples collected during conduction of a prospective DLBCL trial at three different time points, allowing us to analyze sPD-1 and sPD-L1 levels during immunochemotherapy and assess whether the levels were associated with outcome. The gene discussed is SPDL1; the disease is diffuse large B-cell lymphoma.